Roche

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Roche increases offer for Illumina $51 per share

Friday, March 30, 2012 09:17 AM

Roche has increased its offer price for all outstanding publicly-held shares of Illumina, $51 per share in cash. All other terms and conditions of the tender offer remain unchanged.

More... »

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

ICON, Roche in technology partnership

Tuesday, March 6, 2012 01:27 PM

Global CRO ICON has been selected by Roche as its technology partner for storing and managing medical images collected during the company’s clinical research programs.

More... »

Ventana receives FDA clearance for Ki-67 (30-9) image analysis

Tuesday, March 6, 2012 06:06 AM

The FDA has granted Ventana Medical Systems, a member of the Roche Group, 510(k) clearance for its Ventana Companion Algorithm Ki-67 (30-9) image analysis application used with the Ventana iScan Coreo Au scanner running Virtuoso software.

More... »

Roche extends Illumina tender offer

Monday, February 27, 2012 03:17 PM

Roche has extended its cash tender offer to acquire all outstanding shares of Illumina at $44.50 per share to 6 p.m., Eastern Standard Time, on March 23, 2012.

More... »

Illumina’s board unanimously rejects Roche’s offer

Wednesday, February 8, 2012 12:52 PM

Illumina’s board of directors has thoroughly reviewed Roche’s unsolicited tender offer with the assistance of its financial and legal advisors and, according to the company, has unanimously determined that the $44.50 per share cash offer is grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina’s stockholders.

More... »

Illumina adopts stockholder Rights Agreement in response to Roche acquisition plan

Thursday, January 26, 2012 01:22 PM

San Diego-based Illumina said its board of directors has adopted a Rights Agreement, pursuant to which one preferred stock purchase right will be distributed as a dividend on each share of Illumina common stock held of record as of the close of business Feb. 6, 2012 (the “Rights”).

More... »

Roche offers to acquire Illumina to strengthen its diagnostics

Wednesday, January 25, 2012 03:11 PM

Roche is proposing to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.

More... »

Bayer, Ventana collaborate on test for personalized cancer therapy

Wednesday, January 18, 2012 12:05 PM

Bayer Pharma has collaborated with Ventana Medical Systems, a member of the Roche Group, to develop a molecular companion diagnostic test to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC).

More... »